Virbac S.A.
Virbac S.A.
Your view on VRBCF
Overview
What the company does, where it operates, and who runs it.
About Virbac S.A.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Habib Ramdani
- Headquarters
- 13e rue LID - BP 27, Carros, FR
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Habib Ramdani
- Headquarters
- 13e rue LID - BP 27, Carros, FR
Virbac SA manufactures and sells a range of products and services for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, the Middle East, and Africa.
The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners.
Virbac SA was founded in 1968 and is headquartered in Carros, France.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Virbac S.A., and the rating behind it. VRBCF last traded at $346.00, 17.3× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Virbac S.A.. Starting points for Virbac S.A.: P/E 17.3, EPS $17.94, beta 0.86 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Virbac S.A.. Virbac S.A. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Virbac S.A.. Trailing twelve-month EPS for Virbac S.A. stands at $17.94. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Virbac S.A.. Virbac S.A. has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Virbac S.A. valued side by side against its closest peers. Virbac S.A. is measured against Drug Manufacturers - General peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Virbac S.A., and how their positions are changing. At a $2.90B market value, institutional positions materially move Virbac S.A.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Virbac S.A. executives and directors. Shares of Virbac S.A. have traded between $324.00 and $431.80 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Virbac S.A.. Virbac S.A. is a $2.90B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Virbac S.A.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Virbac S.A.. Coverage tracks Virbac S.A. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.